Biogen Buys Apellis for $5.6B to Expand Kidney Drugs
Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company's largest-ever acquisitions.
More from Australia
Immuron hit with 44% first strike vote
Northern Star’s new CEO says performance has fallen short
ASX finds Austral breached rules on A$6.9m deals
Tasmea’s second FY27 guidance upgrade points to 80% earnings growth
MinRes scraps executive exit pay vote as investor support falls short
Woolworths unveils $10b sales growth plan to investors